SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/19/19 Nymox Pharmaceutical Corp 6-K 11/19/19 4:155K e3 Fil… Computershare/FA |
Document/Exhibit Description Pages Size 1: 6-K Report of Foreign Issuer for the Period Ended HTML 9K November 19, 2019 2: EX-99.1 Notice of Annual General Meeting on December 17, HTML 6K 2019 3: EX-99.2 Information Circular HTML 70K 4: EX-99.3 Form of Proxy HTML 22K
Filed by e3 Filing, Computershare 1-800-973-3274 - Nymox Pharmaceutical Corporation - Form 6-K |
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the period ended November 19, 2019
Commission File Number: 001-12033
Nymox Pharmaceutical Corporation
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F [ X ] Form 40-F [ ]
Indicate by check mark if the registrant is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(l): [ ]
Indicate by check mark if the registrant is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ]
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [ X ]
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-______________
Exhibits | |
99.1 | Notice of annual general meeting on December 17, 2019 |
99.2 | Information circular |
99.3 | Form of proxy |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
NYMOX PHARMACEUTICAL CORPORATION | |
(Registrant) |
|
|
|
|
|
By: /s/ Paul Averback, MD | |
Paul Averback, MD | |
President and Chief Executive Officer |
Date: November 19, 2019
This ‘6-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on / For Period end: | 11/19/19 | None on these Dates | ||
List all Filings |